← 返回专利悬崖列表
CAS 108-95-2
Carbolic acidphenolPhenol
登记编号：(I)461018-33-a、ROXA-023、Amoxicillin-006、SOFO-015、IGUR-010、Bisoprolol-001
应用背景（按来源药适应症）
华氏巨球蛋白血症伊布替尼慢性淋巴细胞白血病伊布替尼套细胞淋巴瘤伊布替尼移植物抗宿主病伊布替尼贫血罗沙司他幽门螺杆菌感染阿莫西林/奥美拉唑/利福布汀消化不良阿莫西林/奥美拉唑/利福布汀丙型肝炎索磷布韦/维帕他韦慢性丙型肝炎索磷布韦/维帕他韦终末期肾脏病索磷布韦/维帕他韦肝脏移植排斥索磷布韦/维帕他韦肾脏移植排斥索磷布韦/维帕他韦心脏衰竭索磷布韦/维帕他韦十二指肠溃疡雷贝拉唑钠/甲硝唑/阿莫西林特发性血小板减少性紫癜雷贝拉唑钠/甲硝唑/阿莫西林胃溃疡雷贝拉唑钠/甲硝唑/阿莫西林胃炎雷贝拉唑钠/甲硝唑/阿莫西林幽门螺杆菌感染雷贝拉唑钠/甲硝唑/阿莫西林边缘带B细胞淋巴瘤克拉霉素/雷贝拉唑钠/阿莫西林十二指肠溃疡克拉霉素/雷贝拉唑钠/阿莫西林特发性血小板减少性紫癜克拉霉素/雷贝拉唑钠/阿莫西林胃溃疡克拉霉素/雷贝拉唑钠/阿莫西林胃炎克拉霉素/雷贝拉唑钠/阿莫西林幽门螺杆菌感染克拉霉素/雷贝拉唑钠/阿莫西林类风湿关节炎艾拉莫德移植物抗宿主病艾拉莫德Sjtoegren综合征艾拉莫德高血压苯磺酸氨氯地平/富马酸比索洛尔原发性高血压苯磺酸氨氯地平/富马酸比索洛尔细菌感染阿莫西林钠慢性丙型肝炎索磷布韦丙型肝炎索磷布韦慢性乙型肝炎索磷布韦戊型肝炎病毒感染索磷布韦肝硬化索磷布韦门静脉高血压索磷布韦高血压富马酸比索洛尔心绞痛富马酸比索洛尔慢性阻塞性肺疾病富马酸比索洛尔心脏和血管疾病富马酸比索洛尔急性冠脉综合征富马酸比索洛尔禁食富马酸比索洛尔
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 伊布替尼Ibrutinib | Tier A · 立即攻坚 | 2027 |
| 罗沙司他Roxadustat | Tier C · 观察 / 贸易 | 2028 |
| 阿莫西林/奥美拉唑/利福布汀Amoxicillin/Omeprazole/Rifabutin | Tier C · 观察 / 贸易 | - |
| 索磷布韦/维帕他韦Sofosbuvir/Velpatasvir | Tier B · 提前布局 | - |
| 雷贝拉唑钠/甲硝唑/阿莫西林Rabeprazole Sodium/Metronidazole/Amoxicillin | Tier C · 观察 / 贸易 | - |
| 克拉霉素/雷贝拉唑钠/阿莫西林Clarithromycin/Rabeprazole Sodium/Amoxicillin | Tier C · 观察 / 贸易 | - |
| 艾拉莫德Iguratimod | Tier C · 观察 / 贸易 | - |
| 苯磺酸氨氯地平/富马酸比索洛尔Amlodipine Besylate/Bisoprolol Fumarate | Tier C · 观察 / 贸易 | - |
| 阿莫西林钠Amoxicillin Sodium | Tier C · 观察 / 贸易 | - |
| 索磷布韦Sofosbuvir | Tier B · 提前布局 | - |
| 富马酸比索洛尔Bisoprolol Fumarate | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
2-aminoacetic acid→methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate→phenol→5-bromoisobenzofuran-1(3H)-one→5-phenoxyisobenzofuran-1(3H)-one→2-(chloromethyl)-4-phenoxybenzoyl chloride→methyl 2-(chloromethyl)-4-phenoxybenzoate→methyl tosylglycinate→methyl 2-((N-(2-methoxy-2-oxoethyl)-4-methylphenylsulfonamido)methyl)-4-phenoxybenzoate→methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate→N,N,N',N'-tetramethylmethanediamine→methyl 1-((dimethylamino)methyl)-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate→methyl 1-(acetoxymethyl)-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
Methyl glyoxylate→(S)-(-)-1-Phenylethylamine→(1S)-1-(2-Naphthyl)ethanamine→Methyl (2Z)-[[(1S)-1-phenylethyl]imino]acetate→Methyl (2Z)-[[(1S)-1-(naphthalen-2-yl)ethyl]imino]acetate→Carbolic acid→Methyl (2R)-(4-hydroxyphenyl)[(1-phenylethyl)amino]acetate→Methyl (2R)-(4-hydroxyphenyl)[[1-(naphthalen-2-yl)ethyl]amino]acetate→Methyl (2R)-(4-hydroxyphenyl)[(1-phenylethyl)amino]acetate hydrogen chloride (1/1)→Methyl (2R)-(4-hydroxyphenyl)[[1-(naphthalen-2-yl)ethyl]amino]acetate hydrogen chloride (1/1)→D-p-Hydroxyphenylglycine methyl ester hydrochloride→D-p-yHdroxyphenylglycine methyl ester→(+)-6-Aminopenicillanic acid
1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione→(S)-isopropyl 2-aminopropanoate hydrochloride→1-((2R,3R,4R,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-fluoro-4-hydroxy-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione→4-oxopentanoic anhydride→(2R,3R,4R,5R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-4-methyltetrahydrofuran-3-yl 4-oxopentanoate→(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-yl 4-oxopentanoate→(S)-isopropyl 2-(((R)-(4-nitrophenoxy)(phenoxy)phosphoryl)amino)propanoate→(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-2-((((S)-(((S)-1-isopropoxy-1-oxopropan-2-yl)amino)(phenoxy)phosphoryl)oxy)methyl)-4-methyltetrahydrofuran-3-yl 4-oxopentanoate→phenol→4-nitrophenyl phosphorodichloridate
Methyl glyoxylate→(S)-(-)-1-Phenylethylamine→(1S)-1-(2-Naphthyl)ethanamine→Methyl (2Z)-[[(1S)-1-phenylethyl]imino]acetate→Methyl (2Z)-[[(1S)-1-(naphthalen-2-yl)ethyl]imino]acetate→Carbolic acid→Methyl (2R)-(4-hydroxyphenyl)[(1-phenylethyl)amino]acetate→Methyl (2R)-(4-hydroxyphenyl)[[1-(naphthalen-2-yl)ethyl]amino]acetate→Methyl (2R)-(4-hydroxyphenyl)[(1-phenylethyl)amino]acetate hydrogen chloride (1/1)→Methyl (2R)-(4-hydroxyphenyl)[[1-(naphthalen-2-yl)ethyl]amino]acetate hydrogen chloride (1/1)→D-p-Hydroxyphenylglycine methyl ester hydrochloride→D-p-yHdroxyphenylglycine methyl ester→(+)-6-Aminopenicillanic acid
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | N-(4-glycyl-5-methoxy-2-phenoxyphenyl)methanesulfonamide
hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | N-(5-Methoxy-2-phenoxyphenyl)methanesulfonamide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | N-[4-[(Formylamino)acetyl] -5-hydroxy-2- phenoxyphenyl]methanesulfonamide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 4-hydroxy-1-methyl-7-phenoxy-3-Isoquinolinecarboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 4-hydroxy-1-methyl-7-phenoxy-3-Isoquinolinecarboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | Methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 5-Phenoxyisobenzofuran-1(3H)-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinecarboxylic acid ethyl ester Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinecarboxylic acid methyl ester Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 2'-Deoxy-2'-fluoro-2'- Methyl-N-(phenylcarbonyl) cytidine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 2'-deoxy-2'-fluoro-2'-C-methyluridine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。